Pien Tze Huang hits first daily limit up since last year; policy tailwinds abound for traditional Chinese medicine sector

Industry

โดย 21世纪经济·Read original

Summary · why it matters

Traditional Chinese medicine leader Pien Tze Huang hit its first daily limit up since last year on July 16, closing at the daily limit up price. The traditional Chinese medicine sector continued to climb that day, with ZBD Pharmaceutical also hitting limit up, and Longshenrongfa, Biovalley, Tongrentang and others rising over 5 percent. Pien Tze Huang has been weakening since touching a high of 473.05 yuan in July 2021, falling over 68 percent by July 16, with 129,900 shareholders as of the end of the first quarter of 2026. Recently, policy tailwinds for the traditional Chinese medicine industry have been frequent. The State Council approved the 15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine, and three departments including the National Health Commission released the 2026 edition of the National Essential Medicines List, with the number of proprietary Chinese medicine varieties increasing to 318. Sealand Securities believes the traditional Chinese medicine sector is likely to see an earnings recovery in 2026, with easing cost pressures, and the new essential medicines list will open up medium- to long-term growth potential, suggesting investors pay attention to sector-wide opportunities.

Zhangzhou Pientzehuang Pharmaceutical Co Ltd ▲